Jean-Marie Reimund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jean-Marie Reimund has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Bernard Duclos
Hepato-Gastroenterology & Nutritional Support, Strasbourg University Hospital, Strasbourg Cedex, France
4 shared publications- Matthieu Allez
Department of Gastroenterology, Hôpital Saint-Louis, Paris, France
3 shared publications - Philippe Bachellier
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives, Hépatiques et de la Transplantation, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
3 shared publications Anne-Marie Justum
2 shared publications- Bernard Flourié
Department of Gastroenterology, University Hospital of Lyon, France
2 shared publications Camille Besch
Hepato-Gastroenterology & Nutritional Support, Strasbourg University Hospital, Strasbourg Cedex, France
2 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB209
Sa1315 WAIT-AND-WATCH APPROACH IN PATIENTS WITH ANASTOMOTIC STRICTURES AFTER ORTHOTOPIC LIVER TRANSPLANTATION: IS TREATMENT ALWAYS NECESSARY?
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB209
Sa1315 WAIT-AND-WATCH APPROACH IN PATIENTS WITH ANASTOMOTIC STRICTURES AFTER ORTHOTOPIC LIVER TRANSPLANTATION: IS TREATMENT ALWAYS NECESSARY?
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1505 - Impact of Clinically Evident Portal Hypertension on Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1505 - Impact of Clinically Evident Portal Hypertension on Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S275-S276
CDX2 is a Biomarker of Better Prognosis in Pancreatic Ductal Adenocarcinoma (PDA)
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S275-S276
CDX2 is a Biomarker of Better Prognosis in Pancreatic Ductal Adenocarcinoma (PDA)
- Open Access
- 1 January 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (1) , 232-240
Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer
Inflammatory bowel disease (IBD) exposes patients to an increased risk of colorectal cancer (i-CRC) and differences between i-CRC and sporadic colorectal cancer (s-CRC) pathogenesis were reported. In s-CRC, studies indicate abnormalities in the tumor-suppressor gene Cdx2. This study compared CDX2, β-catenin, and TP53 expression in i-CRC, s-CRC, noncancer IBD, and normal control colonic mucosa. Expression was investigated by immunohistochemistry in 10 normal, 20 s-CRC, 11 noncancer colonic IBD and 30 i-CRC samples, and in four samples of Crohn's disease (CD)-associated small bowel adenocarcinoma (i-SBA). In normal and noncancer IBD samples, CDX2 was confined to the colonocytes nuclei. CDX2 expression was normal in 90% of i-CRC, regardless of tumor differentiation or inflammation intensity. By contrast, CDX2 expression was altered in 45% s-CRC, particularly at the front of invasion in undifferentiated tumors. β-Catenin was restricted to cell membrane in all controls, in 91% noncancer IBD, and in 84% i-CRC samples, whereas 35% s-CRC showed cytoplasmic redistribution and exclusive nuclear staining at the front of invasion. TP53 was strongly and homogeneously expressed in i-CRC nuclei compared to normal control or s-CRC, and increases with inflammation intensity. Nested or diffuse TP53 was found in 81.8% of noncancer IBD samples with a higher proportion of TP53-expressing cells in the most inflamed samples. CDX2, β-catenin, and TP53 expression in CD-associated SBA appears similar to that of i-CRC. Neither Cdx2 nor β-catenin alterations are prominent features of i-CRC. In i-CRC and CD-associated SBA, carcinogenesis is associated early with p53 mutations and to inflammation intensity.
- 1 January 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (1) , 232-240
Open AccessImmunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer
Inflammatory bowel disease (IBD) exposes patients to an increased risk of colorectal cancer (i-CRC) and differences between i-CRC and sporadic colorectal cancer (s-CRC) pathogenesis were reported. In s-CRC, studies indicate abnormalities in the tumor-suppressor gene Cdx2. This study compared CDX2, β-catenin, and TP53 expression in i-CRC, s-CRC, noncancer IBD, and normal control colonic mucosa. Expression was investigated by immunohistochemistry in 10 normal, 20 s-CRC, 11 noncancer colonic IBD and 30 i-CRC samples, and in four samples of Crohn's disease (CD)-associated small bowel adenocarcinoma (i-SBA). In normal and noncancer IBD samples, CDX2 was confined to the colonocytes nuclei. CDX2 expression was normal in 90% of i-CRC, regardless of tumor differentiation or inflammation intensity. By contrast, CDX2 expression was altered in 45% s-CRC, particularly at the front of invasion in undifferentiated tumors. β-Catenin was restricted to cell membrane in all controls, in 91% noncancer IBD, and in 84% i-CRC samples, whereas 35% s-CRC showed cytoplasmic redistribution and exclusive nuclear staining at the front of invasion. TP53 was strongly and homogeneously expressed in i-CRC nuclei compared to normal control or s-CRC, and increases with inflammation intensity. Nested or diffuse TP53 was found in 81.8% of noncancer IBD samples with a higher proportion of TP53-expressing cells in the most inflamed samples. CDX2, β-catenin, and TP53 expression in CD-associated SBA appears similar to that of i-CRC. Neither Cdx2 nor β-catenin alterations are prominent features of i-CRC. In i-CRC and CD-associated SBA, carcinogenesis is associated early with p53 mutations and to inflammation intensity.
- 1 January 2011
- Published by Springer Nature
- p. 1852-1855
Inflammatory Bowel Disease-Associated Cancer
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
T1305 Are Anti-TNFS Able to Close Enterocutaneous Fistula in Crohn's Disease?
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
T1305 Are Anti-TNFS Able to Close Enterocutaneous Fistula in Crohn's Disease?
Les probiotiques, des outils thérapeutiques pour moduler les effets biologiques de la flore intestinale: une introduction
La caractérisation progressive des multiples propriétés de la flore intestinale a incité de nombreuses équipes de chercheurs et de cliniciens à essayer d’en modifier la composition ou la fonction à des fins thérapeutiques. Les probiotiques font partie des outils susceptibles d’interagir non seulement avec la flore intestinale elle-même, mais aussi avec les cellules épithéliales digestives et/ou les cellules immunocompétentes de la lamina propria intestinale. À ce titre, ils ont fait l’objet de nombreuses études, et progressivement, certaines indications — en particulier en pathologie digestive —, pour certains probiotiques, peuvent être retenues. De nombreux travaux restent cependant nécessaires pour essayer de mieux définir quel(s) probiotique(s) privilégier, à quelle posologie, pour quelle durée, et dans quelles indications ? Avec les données récentes concernant les capacités métaboliques de la flore intestinale et son rôle potentiel dans la régulation de certaines voies métaboliques de l’hôte, de nouveaux champs d’investigation s’ouvrent, non seulement relatifs à la physiopathologie de l’obésité, du diabète ou encore des anomalies du métabolisme lipidique, mais également relatifs à leur intérêt thérapeutique potentiel (seuls ou en association avec des prébiotiques) dans ces affections. The Food and Agriculture Organization and the World Health Organization have jointly defined probiotics as “live microorganisms, which when administered in adequate amounts confer a health benefit on the host.” Probiotics have been used for centuries in dairy-based, fermented products. However, their potential use as a form of medical therapy has only recently received formal recognition in the context of a few specific medical conditions, most notably in gastroenterology. The recent identification of the links between the metabolic properties of intestinal flora and host metabolism, including the implication of those links in metabolic diseases like obesity, opens a new field of study focusing on the potential therapeutic use of probiotics in the treatment of metabolic diseases, alone or in combination with prebiotics.
Les probiotiques, des outils thérapeutiques pour moduler les effets biologiques de la flore intestinale: une introduction
La caractérisation progressive des multiples propriétés de la flore intestinale a incité de nombreuses équipes de chercheurs et de cliniciens à essayer d’en modifier la composition ou la fonction à des fins thérapeutiques. Les probiotiques font partie des outils susceptibles d’interagir non seulement avec la flore intestinale elle-même, mais aussi avec les cellules épithéliales digestives et/ou les cellules immunocompétentes de la lamina propria intestinale. À ce titre, ils ont fait l’objet de nombreuses études, et progressivement, certaines indications — en particulier en pathologie digestive —, pour certains probiotiques, peuvent être retenues. De nombreux travaux restent cependant nécessaires pour essayer de mieux définir quel(s) probiotique(s) privilégier, à quelle posologie, pour quelle durée, et dans quelles indications ? Avec les données récentes concernant les capacités métaboliques de la flore intestinale et son rôle potentiel dans la régulation de certaines voies métaboliques de l’hôte, de nouveaux champs d’investigation s’ouvrent, non seulement relatifs à la physiopathologie de l’obésité, du diabète ou encore des anomalies du métabolisme lipidique, mais également relatifs à leur intérêt thérapeutique potentiel (seuls ou en association avec des prébiotiques) dans ces affections. The Food and Agriculture Organization and the World Health Organization have jointly defined probiotics as “live microorganisms, which when administered in adequate amounts confer a health benefit on the host.” Probiotics have been used for centuries in dairy-based, fermented products. However, their potential use as a form of medical therapy has only recently received formal recognition in the context of a few specific medical conditions, most notably in gastroenterology. The recent identification of the links between the metabolic properties of intestinal flora and host metabolism, including the implication of those links in metabolic diseases like obesity, opens a new field of study focusing on the potential therapeutic use of probiotics in the treatment of metabolic diseases, alone or in combination with prebiotics.
- 1 February 2007
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 1 (1) , 21-34
Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Crohns disease is a complex multifactorial disorder characterized by the alternation of a cytokine-driven Tlymphocyte- depending inflammation of the intestinal mucosa, and “off” periods, where patients are completely asymptomatic. Although all the causative factors have not been clearly identified, the continuously growing understanding of the major abnormalities of the inflammatory and immune response leading to the often debilitating symptoms reported by Crohns disease patients, improves our capacity to characterize new potential therapeutic targets with the subsequent hope to discover new (more efficient and less toxic) drugs. Saying that, in the recent years, tumor necrosis factor-alpha undoubtedly emerges as a key cytokine involved in Crohns disease pathogenesis, and constant efforts have been made to control tumor necrosis factor-alpha deleterious effects in Crohns disease. This review schematically summarizes the current understanding of tumor necrosis factor-alphas role in Crohns disease pathogenesis as well as the present and the future treatment strategies which may be helpful in patients by inhibiting tumor necrosis factor-alpha production and effects. Beside drugs under investigation, several original approaches are described or mentioned, most of them leading to recent patents such as polyclonal anti-TNF-alpha antibodies from avian origin, allowing potentially oral administration, or combination strategies such as vitamin D and anti-TNF-alpha antibodies or methotrexate and anti-TNF-alpha antibodies, or decoy oligodeoxynucleotides interfering with the binding of nuclear factor-κB to its target genes promoters.
- 1 February 2007
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 1 (1) , 21-34
Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Crohns disease is a complex multifactorial disorder characterized by the alternation of a cytokine-driven Tlymphocyte- depending inflammation of the intestinal mucosa, and “off” periods, where patients are completely asymptomatic. Although all the causative factors have not been clearly identified, the continuously growing understanding of the major abnormalities of the inflammatory and immune response leading to the often debilitating symptoms reported by Crohns disease patients, improves our capacity to characterize new potential therapeutic targets with the subsequent hope to discover new (more efficient and less toxic) drugs. Saying that, in the recent years, tumor necrosis factor-alpha undoubtedly emerges as a key cytokine involved in Crohns disease pathogenesis, and constant efforts have been made to control tumor necrosis factor-alpha deleterious effects in Crohns disease. This review schematically summarizes the current understanding of tumor necrosis factor-alphas role in Crohns disease pathogenesis as well as the present and the future treatment strategies which may be helpful in patients by inhibiting tumor necrosis factor-alpha production and effects. Beside drugs under investigation, several original approaches are described or mentioned, most of them leading to recent patents such as polyclonal anti-TNF-alpha antibodies from avian origin, allowing potentially oral administration, or combination strategies such as vitamin D and anti-TNF-alpha antibodies or methotrexate and anti-TNF-alpha antibodies, or decoy oligodeoxynucleotides interfering with the binding of nuclear factor-κB to its target genes promoters.